モンテカルロベースのQSARモデリング,分子ドッキング,ADMEプロファイリングを用いたエンドセリン受容体のシリコ設計
Marija Marinković1, Nemanja Nikolić2, Tamara Nikolić3
1Pulmonology Clinic, University Clinical Center Niš, Niš, Serbia.
Journal of molecular graphics & modelling
|August 26, 2025
まとめ
計算モデルにより,心臓血管疾患に対する新しいエンドセリン-1 (ET-1) 反抗剤が成功しました. この研究では,重要な分子断片を特定し,ドッキングとADMEプロファイリングを使用して新しい阻害剤を検証し,薬剤発見を加速しました.
科学分野:
- 薬剤化学
- コンピュータ化学
- 薬理学について
背景:
- エンドセリン-1 (ET-1) は心臓血管疾患の重要な要因であり,ET-1抗剤を主要な治療標的とする.
- 選択的で強力なET-1抗剤の開発は,薬剤発見における重要な課題です.
研究 の 目的:
- 新しいET-1対抗剤の設計のための堅牢な定量構造-活動関係 (QSAR) モデルを開発する.
- 反抗剤の活性に寄与する重要な分子断片を特定する.
- 薬理学的なプロファイルを持つ新しいET-1阻害剤を計算的に設計し,検証する.
主な方法:
- 構成独立のQSARモデルは,分子記述子と局所グラフインヴァリアントを使用して構築された.
- マンテカルロシミュレーションは,ディスクリプター選択とモデル最適化に使用されました.
- コンピュータ支援設計,ETA受容体に対する分子ドッキング,およびADMEプロファイリングが採用されました.
主要な成果:
- 最適なQSARモデルは高い予測精度を示した (r2=0. 9362,q2=0. 9314 訓練用;r2=0. 9006,q2=0. 8655 試験用).
- 6つの新しいET-1阻害剤候補が設計され,ドッキングシミュレーションで有利な結合姿勢と相互作用エネルギーを示した.
- 計算分析により,設計された化合物の好ましいADMEプロファイル,高い薬物類似性,および良好な胃腸吸収が予測されました.
結論:
- QSARと分子ドッキングを統合したシリコ戦略は,ET-1アンタゴニストを発見するための信頼できるパイプラインを提供します.
- 設計された化合物は,実験的検証とさらなる医薬品化学開発の有望な候補です.
- このアプローチは 心血管疾患の新たな治療法の発見を加速します
さらに関連する動画
05:08Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
Published on: July 8, 2025
340
05:47In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
Published on: August 28, 2019
14.1K
関連する概念動画
Structure-Activity Relationships and Drug Design
1.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.0K
Drug Discovery: Overview
8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
224
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
224
Ligand Binding Sites
13.2K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
13.2K
